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The principal feature of Parkinson’s disease (PD) is the impaired ability to acquire
and express habitual-automatic actions due to the loss of dopamine in the
dorsolateral striatum, the region of the basal ganglia associated with the control of
habitual behavior. Dopamine replacement therapy (DRT) compensates for the lack of
dopamine, representing the standard treatment for different motor symptoms of PD
(such as rigidity, bradykinesia and resting tremor). On the other hand, rehabilitation
treatments, exploiting the use of cognitive strategies, feedbacks and external cues,
permit to “learn to bypass” the defective basal ganglia (using the dorsolateral
area of the prefrontal cortex) allowing the patients to perform correct movements
under executive-volitional control. Therefore, DRT and rehabilitation seem to be
two complementary and synergistic approaches. Learning and reward are central
in rehabilitation: both of these mechanisms are the basis for the success of any
rehabilitative treatment. Anyway, it is known that “learning resources” and reward
could be negatively influenced from dopaminergic drugs. Furthermore, DRT causes
different well-known complications: among these, dyskinesias, motor fluctuations, and
dopamine dysregulation syndrome (DDS) are intimately linked with the alteration in
the learning and reward mechanisms and could impact seriously on the rehabilitative
outcomes. These considerations highlight the need for careful titration of DRT to
produce the desired improvement in motor symptoms while minimizing the associated
detrimental effects. This is important in order to maximize the motor re-learning based
on repetition, reward and practice during rehabilitation. In this scenario, we review the
knowledge concerning the interactions between DRT, learning and reward, examine the
most impactful DRT side effects and provide suggestions for optimizing rehabilitation
in PD.
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INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder clinically dominated by bradykinesia, rigidity and
resting tremor. The neuropathological hallmark of PD is
the dopaminergic neuronal loss in the pars compacta of the
substantia nigra (Less et al., 2009). The loss of the physiological
dopaminergic modulation alters the cortico-striatal plasticity
and transforms the basal ganglia into a disruptive filter
(Beeler et al., 2013) that impairs the ability to acquire and
express habitual-automatic movements (Redgrave et al., 2010).
Dopamine replacement therapy (DRT) is the standard treatment
for the motor symptoms of PD: the dopamine precursor
levodopa (L-DOPA), dopamine agonists (DAs), monoamine
oxidase B inhibitors and catechol-O-methyltrasferase inhibitors,
are commonly used. Long-term DRT is able to restore the
physiological synaptic plasticity in the dopamine-denervated
striatum (Calabresi et al., 2015) but might also cause, by
itself, aberrant structural plasticity in the striatal medium
spiny neurons causing further functional short and long term
alterations of neural transmission (Nishijima et al., 2014).
In recent years, rehabilitation has been proposed as effective
and complementary treatment for the management of PD
(Tomlinson et al., 2013; Bloem et al., 2015). Indeed, exercise may
influence neuroplasticity through activity-dependent processes
in the basal ganglia acting on dopaminergic and glutamatergic
neurotransmission (Petzinger et al., 2010). The great value of
rehabilitation is the possibility to treat many disabling PD
disturbances (such as balance dysfunctions, postural instability
and freezing of gait) that do not respond to DRT as they
result from the involvement of systems outside the dopaminergic
structures (e.g., cholinergic, serotoninergic, and noradrenergic;
Calabresi et al., 2013). Rehabilitation exploiting the use of
cognitive strategies, feedbacks and external cues, permits to
bypass the defective basal ganglia using the dorsolateral area
of the prefrontal cortex and allowing the execution of correct
movements under executive-volitional control (Morris, 2006;
Morris et al., 2009). This is possible because motor learning
is feasible in PD subjects, as argued in previous studies
(Nieuwboer et al., 2009). Nevertheless, the long-term DRT
treatment, inducing aberrant structural effects on cortico-striatal
plasticity, could negatively influence the learning process with
the related motivational components subtended by reward
mechanisms (Swainson et al., 2000; Cools et al., 2006; Shohamy
et al., 2006; Jahanshahi et al., 2010; Claassen et al., 2011;
Voon et al., 2011a; Steinberg et al., 2013; Fuhrer et al.,
2014).
Furthermore, DRT causes different well-known
complications: among these, dyskinesias (Obeso et al.,
2005), motor fluctuations (Kikuchi, 2007), and dopamine
dysregulation syndrome (DDS; Lawrence et al., 2003) could
impact seriously on the rehabilitative outcomes. These
side effects are intimately linked with the alteration in the
learning and reward mechanisms: striatum-dependent learning
functions and striatal reward-related motivational processes
are affected in patients with dyskinesias/motor fluctuations and
DDS respectively (Feigin et al., 2003; Cenci and Konradi, 2010).
Learning and reward are central in the motor-cognitive
rehabilitation and the integrity of both of these mechanisms,
as well as the control of the DRT side effects, are the basis
for the success of any rehabilitative approach in PD. Therefore,
given these premises, optimizing drug titration in PD may
be critical for disease management and for good rehabilitative
outcome.
In this article, after discussing the key points for effectiveness
of PD rehabilitation, we review the knowledge concerning
the interactions between DRT, learning and reward,
examine the most impactful DRT side effects and provide
suggestions for optimizing rehabilitation in PD.
REHABILITATION IN PD: KEY POINTS FOR
EFFECTIVENESS
Exercise is beneficial in PD since is able to promote the
so-called ‘‘activity-dependent neuroplasticity’’ (Petzinger et al.,
2010; Frazzitta et al., 2013a). It is defined as modifications
within the central nervous system (CNS) in response to
physical activity that promote a skill acquisition process
(Adkins et al., 2006). Mechanisms by which exercise lead
to these beneficial effects may be through mitigating the
pathological hyperexcitability in basal ganglia cortical circuits
and inducing compensatory changes in dopamine handling
and neurotransmission (Petzinger et al., 2007). Interestingly,
this exercise effect in dopamine release is most pronounced
properly in the dorsolateral striatum, associated with the control
of habitual behavior (Petzinger et al., 2007, 2013). Intensity,
specificity, difficulty and complexity of practice appear to be
important parameters for driving this phenomenon (Petzinger
et al., 2010). Petzinger et al. (2007) in a mice model of PD found
that high intensity exercise determines improvements in running
velocity, endurance and on a motor task designed to assess
balance. A significant clinical improvement after intensive and
goal-based rehabilitation treatment was also found in humans
(Frazzitta et al., 2015), confirming that specific motor training
could exploit the physiological mechanisms of neural plasticity
(Petzinger et al., 2013; Frazzitta et al., 2014; Fontanesi et al.,
2015).
The bases for effective rehabilitation involve several important
recommendations that are consistent with model. These authors
Fitts and Posner’s (1967) proposed that the capability to learn
a motor skill involves three stages: (1) a ‘‘cognitive stage’’ that
involves executive functions for identification and development
of different parts of the movement with formation of a mental-
motor schema; (2) an ‘‘associative stage’’ built on reward-based
decision-making, in which specific environmental feedbacks are
required to achieve the goal; and (3) an ‘‘autonomous stage’’ in
which automaticity is achieved.
Different brain circuits, including prefrontal cortex and basal
ganglia, are involved in reward-based decision-making and
motor learning, and dopamine plays a modulatory role in these
functions (Schultz, 2002). Motor learning in PD is negatively
affected throughout the automatization phase (Doyon et al.,
2009; Nieuwboer et al., 2009) Given that, the main purpose
of rehabilitation in PD should be the re-acquisition of the lost
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automatic movements through executive-volitional control that
is the ability to initiate habits using goal-directed triggers.
On these bases, Morris et al. (2010) showed that external
cues, such as lines on the floor, visualizing the walk with long
steps, imagining the movement pattern before the action is
performed, breaking down long or complex motor sequences
into parts, enabled people with PD to walk with longer steps
and at a more normal stepping rate, reducing move and
balance difficulty (Morris et al., 1994, 1996, 2009; Morris, 2006).
Furthermore, the use of treadmill, acting as an external cue,
enhances gait rhythmicity and reduces gait variability improving
walking in Parkinsonian patients (Frenkel-Toledo et al., 2005;
Frazzitta et al., 2009, 2013b). These strategies exploits executive
functions and represent the basis to re-learn motor skills in PD
(Nieuwboer et al., 2009).
Further, in order to maximize learning, is crucial the ability
to associate stimuli with actions that lead to rewarding outcomes
(vanWouwe et al., 2012). Therefore, in the following sections, we
will explore the impact of DRT on learning and reward.
THE IMPACT OF DRT ON LEARNING AND
REWARD
Although the basal ganglia are traditionally known to contribute
to motor function, more recently they have been shown to be
engaged in several types of learning, including habit formation,
procedural skill learning, and reward-based decision-learning
(van Wouwe et al., 2012). Therefore, involving the disruption
of basal ganglia, PD provides an informative naturalistic
model for understanding the role of dopamine in reward and
learning. Although DRT successfully improves motor deficits
in PD, its effects on cognitive and motivational processes
are more equivocal. The fact that DRT acts differentially on
such circuits has been explained in terms of an ‘‘overdose
theory’’ (Cools, 2006; Torta et al., 2009). There are two
main dopamine pathways in the brain: (1) the nigrostriatal
pathway, responsible for voluntary movements, is the target
area for treating motor symptoms in PD and is associated with
activation in dorsolateral striatum; and (2) themesocorticolimbic
pathway, strongly associated with reward and motivation-
related processes, involves the activation of the ventral portions
of the striatum (see Figure 1; Wise, 2009). In the early
stages of PD the ventral striatal dopamine projections are
relatively preserved, and the dopaminergic drugs lead to
an ‘‘overflow’’ of dopamine in the ventral striatum and
mesocorticolimbic system. This fact causes problems in reward
and in the motivational-related processing (Claassen et al.,
2011; Voon et al., 2011a), leading to maladaptive decision-
making and compulsive behaviors (Swainson et al., 2000).
While DRT ameliorates the task associated with the dorsal
fronto-striatal circuitry, such as cognitive flexibility (Cools,
2006), the excessive levels of dopamine in mesocorticolimbic
system alter striatal reward prediction error (RPE) activity,
i.e., the difference between expected and actual reward. The
RPE signal is needed to optimize behavior and learning.
In physiological conditions, a negative RPE is conveyed
by pauses in dopamine neuron firing (Bayer et al., 2007).
Instead, in medicated PD patients, persistent postsynaptic
dopamine stimulation may reduce the ability of these pauses
to influence learning, impairing the ability to learn from
negative consequences and resulting in increased engagement
in reward-seeking behaviors (Frank et al., 2004; Cools et al.,
2006).
In this scenario, it has also been found that DRT has
a detrimental effect on habit learning (Fuhrer et al., 2014),
on error-correcting and feedback-based learning processes
(Shohamy et al., 2006) and impairs reversal shifting in
those conditions where reversals are signaled by unexpected
punishment (Cools et al., 2006). The deterioration of these
forms of learning supports the proposal that tonic dopaminergic
increase masks phasic changes in dopamine release essential for
learning in medicated PD patients (Jahanshahi et al., 2010).
THE IMPACT OF DRT SIDE EFFECTS
The most impactful DRT side effects consist in dyskinesias,
motor fluctuations and DDS. Common neurophysiopathological
mechanisms involving the cortico-striatal plasticity link these
motor and behavioral side effects (Voon et al., 2009, 2011a,b).
Dyskinesias refer to a category of movement disorders that
are characterized by involuntary muscle movements. They occur
in more than half of PD patients after 5–10 years of L-DOPA
treatment, with the percentage of affected patients increasing
over time (Obeso et al., 2005). They commonly present as chorea
or choreoathetosis, though myoclonus, akathasia, ballism and
other forms of abnormal movements. They lead to exhaustion,
fatigue, risk of injury and weight loss causing pronounced
discomfort and physical limitation. If dyskinesias becomes too
severe impair the patient’s quality of life and a reduction in
L-DOPA might be necessary.
Motor fluctuations, such as wearing-off and on–off effect, are
approximately experienced by 40% after 4–6 years of treatment
with L-DOPA, similar to the frequency of dyskinesias (Kikuchi,
2007). Wearing off is the most common motor fluctuation
seen in patients with PD. With this pattern, patients develop a
predictable worsening of their parkinsonism at the end of the
dose because of the short duration benefit after a given dose of
L-DOPA. With disease progression the dosing response varies
and patients may report a ‘‘delayed-on’’ or ‘‘no-on’’ (Kikuchi,
2007). On-off fluctuations are characterized by sudden and
unpredictable shifts between on and off state.
DDS represents a pattern of addictive drug use: it occurs
in 3–4% of PD patients treated with DRT although this
phenomenon is probably under-diagnosed (Merims and Giladi,
2008). DDS is predominately reported in patients receiving
L-DOPA, but the development of this ‘‘addiction-like’’ behavior
has been found also in patients using DAs and apomorphine
(Giovannoni et al., 2000; Lawrence et al., 2003; Witjas et al.,
2005; Merims and Giladi, 2008). Parkinsonian patients with
DDS rapidly develop a pattern of compulsive DRT-seeking,
leading to the intake of high daily L-DOPA doses. Patients
eagerly wait for ignition of the ‘‘on’’ period after an oral dose
of L-DOPA (Merims and Giladi, 2008). In the ‘‘off’’ period,
they are often agitated, depressed and anxious resembling
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FIGURE 1 | Dopaminergic pathways and the role of dopamine in reward, compulsive behavior and addiction. Although dopamine replacement therapy
(DRT) successfully improves motor deficits in Parkinson’s disease (PD), its effects on cognitive and motivational processes are more equivocal. This is related to the
effect that DRT exercises on the different dopaminergic pathways: the nigrostriatal pathway, responsible for voluntary movements, connects the substantia nigra with
the dorsal striatum; the mesocorticolimbic pathways, associated with reward and motivation-related processes, connect the ventral tegmental area to the ventral
striatum and the cerebral cortex (in particular the frontal lobes). In the early stages of PD the ventral striatal dopamine projections are relatively preserved, and the
dopaminergic drugs lead to an “overflow” of dopamine in the ventral striatum and mesocorticolimbic system. This overflow is responsible for the problems in reward
(due to disruption of the dopaminergic input to mesolimbic pathway), motivational-related processing and maladaptive decision-making (due to disruption of the
dopaminergic input to mesocortical pathway), impaired ability to learn from negative consequences with compulsive behaviors and impulsivity (due to alteration of
dopaminergic input to ventral striatum). Drug addiction, related to the disruption of the dopaminergic input to dorsal striatum represents a pathological shift form
voluntary drug use to more habitual and compulsive drug intake. The alteration in the learning and reward mechanisms could impact seriously on the rehabilitative
outcomes. Thus, it is necessary to titrate carefully DRT to produce the desired improvement in motor symptoms while minimizing the associated detrimental effects.
withdrawal phenomena exhibited by drug addicts (Hughes
et al., 1994). In extreme cases, patients will report only
feeling ‘‘on’’ and ‘‘mobile’’ when notably dyskinetic and
deliberately exaggerate the description of their clinical status
to get more medication from the doctor (Lawrence et al.,
2003).
OPTIMISING REHABILITATION IN PD
As argued before, the rehabilitative interventions in PD should
be based on repetition and practice: several intensive and
specific approaches drive the re-acquisition of the lost automatic
movements exploiting executive functions and the ability to
initiate habits using goal-directed triggers (a summary of
the aims of rehabilitation on PD symptoms may be found
in Table 1). Frazzitta et al. (2012b, 2015) demonstrated
that a multidisciplinary and intensive rehabilitative treatment,
designed according to these concepts, acts positively on early
PD, possibly influencing the natural progression of motor
impairment and reducing the need for increasing DRT. The
patients enrolled in these studies underwent very intensive and
goal-based treatment that included physical exercises and the
use of a number of devices, such as a stabilometric platform
and a treadmill with auditory and visual cues (Frazzitta et al.,
2009). Similarly, Ellis et al. (2008) studied in inpatients with
PD the efficacy of an intensive program: after treatment,
all patients showed significant improvements in motor and
functional evaluated outcomes. Corcos et al. (2013) reported that
progressive resistance exercise improved motor performances
in PD patients with an effect lasting up to 2 years. Shulman
et al. (2013) suggested the importance of a combination of
treadmill training and resistance exercise to obtain a greater
benefit in patients with PD. According to all these findings,
Fisher et al. (2008) previously showed that high intensity
exercise could normalize corticomotor excitability (assessed
with cortical silent period durations in response to single-pulse
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TABLE 1 | The aims of rehabilitation on Parkinson’s disease (PD) symptoms.
Aim Implications for Rehabilitation
Reacquisition of automatic movements Teaching to utilize PFC instead of basal ganglia through volitional control to regulate
movement
Improve impaired ability to acquire and express habitual-automatic actions Repetition and practice of actions supported by DRT management
Motor learning Motor learning-based rehabilitation in addition to DRT
Avoid compulsive DRT use Rehabilitation in off period using correct levodopa dose
Abbreviations: DRT, dopamine replacement therapy; PFC, Pre-frontal cortex.
transcranial magnetic stimulation) in early PD, suggesting
that high-intensity exercise may induce activity-dependent
neuroplasticity.
It was also shown that intensive and goal-based rehabilitation
treatments allow a reduction in dyskinesias (Frazzitta et al.,
2012a,c): data from animal models show that in PD striatal
plasticity is lost, but chronic L-DOPA treatment is able to
restore the long-term potentiation of synaptic transmission
(Centonze et al., 2001). The reversal of synaptic strength
from the potentiated levels is called depotentiation, and this
learning process represents a mechanism for erasing unnecessary
motor information. In L-DOPA-induced dyskinesias, synaptic
depotentiation is lost possibly representing the cellular basis of
dyskinesias (Picconi et al., 2003). Exaggerated movements in
response to a stimulation of dopaminergic receptors, such as
those occurring during dyskinesias, might consequently convey
erroneous information to the motor striate circuits. Therefore,
when concomitant, competing correctmovements are performed
(as during rehabilitation treatment), the manifestation of
abnormal dyskinetic movements may be attenuated (Frazzitta
et al., 2012a,c).
As a matter of fact it seems that DRT on one side, stimulating
the dopamine-denervated striatum, and rehabilitation on the
other side, promoting the activity-dependent neuroplasticity,
are synergistically able to exploit the physiological mechanisms
of cortico-striatal plasticity in PD. Nevertheless, in medicated
patients, in the early stages of PD, the differences between
nigrostriatal and mesolimbic dopaminergic denervation may
induce a ‘‘hyperdopaminergic state’’ in the mesocorticolimbic
system that alter the reward-related learning mechanisms
(Calabresi et al., 2015). This ‘‘state’’ may interfere with
synaptic plasticity properly in the area of basal ganglia
involved in habit formation (Bowers et al., 2010; Lüscher and
Malenka, 2011; Madsen et al., 2012) and could determine
the phenomenon of DDS by creating powerful drug-related
pathological memories (Hyman, 2005; Robbins et al., 2008;
Simola et al., 2013).
The chronic administration of DRT induces also pronounced
hyperdopaminergic stimulation in the nigrostriatal system. This
non-physiological stimulation represents a critical factor in the
development of dyskinesias: in cynomolgus monkeys, Aubert
et al. (2005) demonstrated the central role of the dopamine-D1
receptors (D1Rs), that are co-expressed in the direct pathway
neurons with dopamine-D3 receptors, in the pathogenesis of
L-DOPA-induced dyskinesias. Particularly, they found that
the D1R expression and responsiveness are increased after
L-DOPA treatment and that the sensitivity of the D1R signaling
cascade is enhanced in L-DOPA-induced dyskinesias (Aubert
et al., 2005). Since dopamine-D2 receptor levels expressed by
medium spiny neurons of the indirect pathway are neither
normalized nor increased after L-DOPA treatment, these authors
supported the hypothesis of a predominant role for the direct
pathway in L-DOPA-induced dyskinesias (Aubert et al., 2005).
In this scenario, it is known that increased responsiveness
of the D1R machinery to L-DOPA results in augmented
synthesis of cyclic adenosine monophosphate (cAMP), hyper-
activation of cAMP-dependent protein kinase (PKA) and cAMP-
dependent phosphoprotein of 32 kDa (DARPP-32; Feyder
et al., 2011). Abnormal PKA/DARPP-32 signaling increases the
phosphorylation of glutamate receptor 1 (Feyder et al., 2011).
This effect promotes the excitability of striatal medium spiny
neurons and may participate in the loss of corticostriatal long-
term depression and depotentiation. Further, sensitized D1R-
mediated transmission leads also to activation of extracellular
signal-regulated kinases (ERK) and the mammalian target of
rapamycin complex 1 (mTORC1), which control transcriptional
and translational processes (Santini et al., 2010; Feyder et al.,
2011). As in a vicious cycle, all these effects related to this
persistent and excessive stimulation of D1Rs exacerbate the
dyskinetic motor behavior.
Therefore, while DDS is related to affected striatal reward-
related motivational processing, dyskinesias and motor
fluctuations represent the inability of striatal neurons to
dynamically gate correct cortically driven motor commands
(Cenci and Konradi, 2010). This worsens striatum-dependent
learning functions (Feigin et al., 2003) with detrimental effects
on motor performances. Contrariwise, as previously said,
DRT ameliorates cognitive flexibility (Cools, 2006). Thus,
dopaminergic neurons regulates cognition in according to an
‘‘inverted-U’’ shaped function, so that too little or too much
activity has detrimental effects on executive functions and
learning performances depending on the specific task demands
(Cools, 2006). All these functional, neuropsychological and
biological findings highlight the need for careful DRT titration.
Warren Olanow et al. (2013) found a relative L-DOPA threshold
effect, with a marked increase in the risks of developing
dyskinesias and wearing-off at L-DOPA doses ≥400 mg/day.
Based on the results from this study, clinicians should initiate
L-DOPA treatment with low doses, proceed by small increments
and avoid a total L-DOPA amount >400 mg/day (Warren
Olanow et al., 2013).
In addition, the association between DAs dosage and
the emergence of pathologic behaviors (Kelley et al., 2012) must
be taken into account in the clinical practice. Also in this case, the
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discontinuation of the DAs or significant adjustment in dosage
is the mainstay of treatment intervention (Mamikonyan et al.,
2008).
The dopaminergic drugs titration is fundamental with
respect to rehabilitation: high levels of DRT induce motor and
behavioral side effects and a related negative impact on learning
and reward mechanisms, reducing the possibility to achieve good
rehabilitative results. Considering that, not disease duration, but
DRT dosage accounts for the effectiveness of medication in
reducing the reward-based learning (van Wouwe et al., 2012),
it is important to promote a synergistic and complementary
action between DRT and rehabilitative efforts. PD patients
should initiate the rehabilitative treatment as soon as possible
and the clinicians should prescribe the ‘‘optimal’’ drug dose.
This is fundamental to exploit the DRT efficacy in restoring
the abnormal cortico-striatal plasticity (fundamental for skills
building) without exhibiting the above-mentioned long-term
dopaminergic side effects that are detrimental for rehabilitation.
This is critical for optimal PD management. A more
comprehensive study of the interactions between disease, DRT,
learning and reward mechanisms is required to deepen the
understanding about a complex treatment of a disorder such
as PD.
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